Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

By LabMedica International staff writers
Posted on 06 Jun 2025

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess immune protection. More...

Conventional methods require large blood samples and lengthy processing times. Now, researchers have developed a compact diagnostic platform, known as the Tip Optofluidic Immunoassay (TOI), that can evaluate antibody protection using just a single microliter of fingertip blood, delivering results in only 40 minutes.

The TOI platform was developed by scientists at Shenzhen Institutes of Advanced Technology (SIAT, Guangdong, China) and the Chinese Academy of Sciences (CAS, Beijing, China), in collaboration with multiple research partners. The initiative brings together expertise in biosensing, microfluidics, and synthetic biology to meet the growing need for accessible, field-ready diagnostic solutions. TOI works by integrating microfluidic biosensing with chemiluminescence detection in a portable format. At its core are high-affinity polystyrene immuno-reactors, which interface directly with standard pipette tips. These reactors are used in tandem with a portable chemiluminescent imaging station, enabling rapid and quantitative measurement of IgG binding levels, binding kinetics, and virus inhibition—all from a tiny drop of fingertip blood. The system operates without the need for complex lab equipment or high sample volumes.

Compared to standard assays like ELISA or virus neutralization tests (VNTs), TOI significantly reduces both processing time and operational complexity. It delivers detection sensitivity at around 0.1 ng/mL, spans a dynamic range of 3 to 4.5 orders of magnitude, and achieves a signal-to-noise ratio of over 10,000. One of the platform’s key innovations is RIVIA 2.0, a rapid in vitro inhibition assay designed to simulate viral neutralization. Using rationally engineered SARS-CoV-2 spike ectodomain (S-ECD) trimers tagged with orientation-specific Avi-biotin, the system achieves precise and reproducible antibody activity measurements in just 20 minutes. The system was validated using 135 blood samples from 113 individuals, with a subset monitored over six months. TOI successfully identified broad-spectrum, high-titer antibody responses, especially in individuals with hybrid vaccine regimens.

Researchers also proposed a preliminary IgG concentration threshold of ~20 ng/mL, potentially linked to reduced short-term infection risk, indicating the test’s potential for predictive immune monitoring. Beyond COVID-19, the platform’s low sample requirement and portability make it suitable for other infectious diseases such as influenza and hepatitis, and for deployment in remote or resource-limited settings. TOI also offers valuable applications in therapeutic antibody development and vaccine efficacy studies, making it a versatile tool for both clinical and research use. This study demonstrates how TOI bridges the gap between advanced laboratory diagnostics and real-world application. By combining speed, sensitivity, and multi-dimensional immune assessment in a highly compact format, TOI sets a new benchmark for personalized and scalable infectious disease management.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Electrolyte Analyzer
BKE-B
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.